Growing Product Portfolio Pharmascience has consistently launched new generic and branded pharmaceutical products, including treatments for allergic rhinitis, thrombosis, and autoimmune conditions, indicating ongoing product innovation and expanding market offerings.

Strong Domestic Presence As the largest pharmaceutical employer in Quebec with a dedicated manufacturing base in Canada, Pharmascience presents opportunities for local sourcing, partnerships, and supply chain collaborations for organizations seeking reliable Canadian pharmaceutical suppliers.

Global Expansion Efforts With products distributed in over 50 countries and ongoing investments in R&D, Pharmascience demonstrates global growth potential, making it a viable partner for international supply chain expansion and joint development ventures.

Innovation and R&D Investment Ranked among Canada’s top R&D investors with $40-50 million invested annually, Pharmascience is poised for new product development, opening opportunities for collaborations on innovative therapies and clinical research projects.

Financial Stability With revenues approaching one billion dollars and recent funding of $55 million, Pharmascience shows strong financial health, making it a secure partner for volume-based supply agreements and long-term business development initiatives.